CO2022000575A2 - Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico - Google Patents

Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico

Info

Publication number
CO2022000575A2
CO2022000575A2 CONC2022/0000575A CO2022000575A CO2022000575A2 CO 2022000575 A2 CO2022000575 A2 CO 2022000575A2 CO 2022000575 A CO2022000575 A CO 2022000575A CO 2022000575 A2 CO2022000575 A2 CO 2022000575A2
Authority
CO
Colombia
Prior art keywords
hydroxybenzoyl
egf
amino
caprylic acid
salt
Prior art date
Application number
CONC2022/0000575A
Other languages
English (en)
Inventor
Andreas Vegge
Betty Lomstein Pedersen
Birgitte Nissen
Kaisa Naelapää
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CO2022000575A2 publication Critical patent/CO2022000575A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden un inhibidor de PCSK9, tal como un péptido de EGF(A), y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico. La invención se refiere además a procesos para la preparación de dichas composiciones, y a su uso en medicina.
CONC2022/0000575A 2019-08-07 2022-01-24 Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico CO2022000575A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19190506 2019-08-07
PCT/EP2020/072227 WO2021023855A1 (en) 2019-08-07 2020-08-07 Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
CO2022000575A2 true CO2022000575A2 (es) 2022-04-29

Family

ID=67551283

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0000575A CO2022000575A2 (es) 2019-08-07 2022-01-24 Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico

Country Status (14)

Country Link
US (1) US20220323544A1 (es)
EP (1) EP4009958A1 (es)
KR (1) KR20220046565A (es)
CN (1) CN114222581A (es)
AR (1) AR122299A1 (es)
AU (1) AU2020326265A1 (es)
BR (1) BR112022000529A2 (es)
CA (1) CA3144618A1 (es)
CO (1) CO2022000575A2 (es)
IL (1) IL289505A (es)
MX (1) MX2022000889A (es)
PE (1) PE20220486A1 (es)
TW (1) TW202120118A (es)
WO (1) WO2021023855A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117979958A (zh) * 2021-07-15 2024-05-03 诺和诺德股份有限公司 包含n-(8-(2-羟基苯甲酰基)氨基)辛酸盐的片剂
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US7544833B2 (en) 2006-09-07 2009-06-09 Hoffmann-La Roche Inc. Methods for producing N-(8-[2-hydroxybenzoyl]-amino) caprylic acid
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
JP2014519848A (ja) 2011-06-20 2014-08-21 ジェネンテック， インコーポレイテッド Ｐｃｓｋ９結合ポリペプチドと使用方法
CN104203221A (zh) * 2012-03-22 2014-12-10 诺和诺德A/S（股份有限公司） 包含递送剂的组合物及其制备
WO2013139694A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
ES2916998T3 (es) 2016-01-13 2022-07-06 Novo Nordisk As Análogos del EGF(A) con sustituyentes de ácidos grasos
CN109475593A (zh) * 2016-06-24 2019-03-15 豪夫迈·罗氏有限公司 用于治疗心血管疾病的组合物和方法
US20200165313A1 (en) 2017-07-19 2020-05-28 Novo Nordisk A/S Egf(a) analogues, preparation, formulations and uses thereof

Also Published As

Publication number Publication date
AR122299A1 (es) 2022-08-31
MX2022000889A (es) 2022-02-14
IL289505A (en) 2022-02-01
BR112022000529A2 (pt) 2022-03-03
PE20220486A1 (es) 2022-04-04
TW202120118A (zh) 2021-06-01
WO2021023855A1 (en) 2021-02-11
KR20220046565A (ko) 2022-04-14
CN114222581A (zh) 2022-03-22
EP4009958A1 (en) 2022-06-15
CA3144618A1 (en) 2021-02-11
AU2020326265A1 (en) 2022-02-03
US20220323544A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
CO2020009997A2 (es) Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
CL2020002797A1 (es) Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2022005904A2 (es) Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2022000575A2 (es) Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2022000578A2 (es) Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CL2019003324A1 (es) Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745)
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
ECSP21067816A (es) Formulaciones farmacéuticas
ECSP21060917A (es) Formulación de anticuerpos terapéuticos
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
CL2017003201A1 (es) Variantes de il-37
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
ES2517741B1 (es) Composición para reducir y/o prevenir la caída del cabello y/o estimular su crecimiento
BR112018070626A2 (pt) formulação farmacêutica, e, composto ou composição para uso, uso, método ou composição
CO2024000581A2 (es) Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
AR122297A1 (es) Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2024000463A2 (es) Forma polimórfica a de n-(8-(2- hidroxibenzoil)amino)caprilato de sodio
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas